Avidity Biosciences

NMQ:RNA · US05370A1088

BiotechnologySmall

360° View

Value25

Price/Sales6

Price/Earnings83

Price/Book19

Dividend Yield—

Growth71

Revenue Growth28

Profit Growth6

Capital Growth73

TSR 52w77

Safety51

Leverage75

Liquidity25

Refinancing46

Combined52

Sentiment25

Analyst Opinions5

Pro Holdings1

Opinion Changes1

Market Pulse72

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePrivate Company

ExchangeNASDAQGM

Founded2012

Employees416

Websiteaviditybiosciences.com

ISINUS05370A1088

Last UpdateApr 2, 2026

Index & Theme

NeurologyCardiovascularImmunologyGeneticsGenetic DisorderBiotechnologyHealth CareLife SciencePharmaceuticalTherapeutics

Description

Avidity Biosciences, Inc. (Avidity) is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company’s proprietary AOC platform is designed to combine the specifi…

Analysis

Avidity Biosciences's 360° View rank of 28 places it below its peer average — better than 28% of its true peers.

It's growing solidly (71) and expensive versus peers (25). On safety it is financially sound (51), and the market shows skeptical sentiment (25). Taken together, its Combined rank of 52 reads as above its peer average.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Avidity Biosciences with its peers

Dyne Therapeutics

NSQ:DYN

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tyra Biosciences

NSQ:TYRA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

C4 Therapeutics

NSQ:CCCC

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

PepGen

NSQ:PEPG

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Arrowhead Pharmaceuticals

NSQ:ARWR

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Nurix Therapeutics

NMQ:NRIX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →